These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277 [TBL] [Abstract][Full Text] [Related]
14. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Kosmider O; Gelsi-Boyer V; Cheok M; Grabar S; Della-Valle V; Picard F; Viguié F; Quesnel B; Beyne-Rauzy O; Solary E; Vey N; Hunault-Berger M; Fenaux P; Mansat-De Mas V; Delabesse E; Guardiola P; Lacombe C; Vainchenker W; Preudhomme C; Dreyfus F; Bernard OA; Birnbaum D; Fontenay M; Blood; 2009 Oct; 114(15):3285-91. PubMed ID: 19666869 [TBL] [Abstract][Full Text] [Related]
15. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558 [No Abstract] [Full Text] [Related]
16. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review]. Guo J; Chang CK; Li X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676 [TBL] [Abstract][Full Text] [Related]
17. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Jain P; Tang G; Konoplev SN; Kanagal-Shamanna R; Wang SA; Pemmaraju N; Daver N; Estrov Z Am J Hematol; 2016 Mar; 91(3):354-5. PubMed ID: 26437693 [No Abstract] [Full Text] [Related]
18. [Mutation of tet2 gene and malignant blood disease]. Qian XF; Shen YF; Zhang SJ; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337 [TBL] [Abstract][Full Text] [Related]
19. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M; Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260 [TBL] [Abstract][Full Text] [Related]
20. Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. Dambruoso I; Boni M; Rossi M; Zappasodi P; Calvello C; Zappatore R; Cavigliano PM; Giardini I; Rocca B; Caresana M; Astori C; Cazzola M; Castagnola C; Bernasconi P Cancer Genet; 2012 Jun; 205(6):285-94. PubMed ID: 22749034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]